BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 7588092)

  • 1. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
    Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
    Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem: a review of its use in the treatment of serious bacterial infections.
    Baldwin CM; Lyseng-Williamson KA; Keam SJ
    Drugs; 2008; 68(6):803-38. PubMed ID: 18416587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem: a review of its use in patients in intensive care.
    Hurst M; Lamb HM
    Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative review of the carbapenems.
    Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
    Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem: an updated review of its use in the management of intra-abdominal infections.
    Lowe MN; Lamb HM
    Drugs; 2000 Sep; 60(3):619-46. PubMed ID: 11030471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
    Balfour JA; Bryson HM; Brogden RN
    Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem, a new carbapenem antibiotic.
    Fish DN; Singletary TJ
    Pharmacotherapy; 1997; 17(4):644-69. PubMed ID: 9250544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C;
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preclinical evaluation of meropenem, a new parenteral carbapenem].
    Edwards JR
    New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem.
    Linden P
    Drug Saf; 2007; 30(8):657-68. PubMed ID: 17696578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of meropenem, a new carbapenem antibiotic.
    Craig WA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S266-75. PubMed ID: 9126702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
    Tonelli F
    Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group.
    Romanelli G; Cravarezza P
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of meropenem in the treatment of serious infections in children: review of the current literature.
    Arrieta A
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S207-12. PubMed ID: 9126695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Buckley MM; Brogden RN; Barradell LB; Goa KL
    Drugs; 1992 Sep; 44(3):408-44. PubMed ID: 1382937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL; Smith JW; Geckler RW; Wilson SE
    South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem: a new carbapenem antimicrobial.
    Pryka RD; Haig GM
    Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.